Ganaxolone vs Stiripentol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Ganaxolone
Marketed by Immedica Pharma AB
NCT01963208 · Phase 3 · completed
The primary phase was well controlled, with randomized quadruple blinding, placebo comparison, and 350 analyzed participants, and it used the clinical endpoint of change in seizure frequency. However, the primary endpoint was missed: the difference between ganaxolone and placebo was not statistically significant (p=0.1788), so the study provides well-designed but inconclusive evidence.
Reported efficacy
Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes); Percentage of Participants With no Progression to Intravenous (IV) Anesthesia for 36 Hours Following Investigational Product (IP) Initiation (Up to 36 hours after IP initiation); Number of Participants With Treatment Emergent Adverse Events (Up to 4 weeks after IP initiation): Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741) (mixed)
Result source: NCT04391569
Stiripentol
Marketed by Biocodex
NCT07176832 · Phase 1 · completed
This is an open-label pharmacokinetic bioequivalence study comparing two formulations of the same already-marketed drug in healthy volunteers, not a controlled trial measuring clinical efficacy against a comparator or placebo.
No aligned efficacy figure on record for this race.
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ganaxolone | Stiripentol |
|---|---|---|
| Seizure frequency, % change | -7.5% vs 13.6%−21.1 vs placeboNCT053237344 other results
| —Not reported |
| 50% responder rate | 18.8% vs 12.3%+6.5 vs placeboNCT053237343 other results
| —Not reported |
| Seizure freedom | 0% vs 2.2%−2.2 vs placeboNCT004655172 other results
| —Not reported |
Seizure frequency, % change
- Ganaxolone
- -7.5% vs 13.6%−21.1 vs placeboNCT05323734
4 other results
- -61.5% vs -24.0% NCT03865732
- -17.6% vs 2.0% NCT00465517
- -12.1% vs 4.6% NCT00465517
- -35.9% vs -18.7% NCT03865732
- Stiripentol
- —Not reported
50% responder rate
- Ganaxolone
- 18.8% vs 12.3%+6.5 vs placeboNCT05323734
3 other results
- 23.5% vs 14.3% NCT00465517
- 25.5% vs 12.2% NCT00465517
- 50% vs 36.4% NCT03865732
- Stiripentol
- —Not reported
Seizure freedom
- Ganaxolone
- 0% vs 2.2%−2.2 vs placeboNCT00465517
2 other results
- 1% vs 0% NCT00465517
- 16.8% vs 8.3% NCT00465517
- Stiripentol
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Stiripentol: no structured comparison results are available for Epilepsy.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ganaxolone: 4 of 4 rows · Stiripentol: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ganaxolone |
|---|---|
| Dropout rate | 4.2%Double Blind: Cohort 1 - Ganaxolona NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 show 16 more results24.6%Double Blind: Cohort 2 - Ganaxolon NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 —Open Label: Ganaxolone in Double-b NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 —Open Label: Placebo in Double-blin NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 41.2% NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3 14.1% NCT05323734 · Phase 3 · registry result, not featured evidence 10% NCT03865732 · Phase 2 · registry result, not featured evidence 12.5%High NCT03350035 · Phase 2 · registry result, not featured evidence 40%Low NCT03350035 · Phase 2 · registry result, not featured evidence 0%Medium NCT03350035 · Phase 2 · registry result, not featured evidence 42.9%CDKL5 NCT02358538 · Phase 2 · registry result, not featured evidence 100%CSWS NCT02358538 · Phase 2 · registry result, not featured evidence 50%Lennox-Gastaut NCT02358538 · Phase 2 · registry result, not featured evidence 45.5%PCDH19 NCT02358538 · Phase 2 · registry result, not featured evidence 95.1% NCT00512317 · Phase 2 · registry result, not featured evidence 36.4% NCT01002820 · Phase 2 · registry result, not featured evidence 12.2% NCT00465517 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 4.2%Double Blind: Cohort 1 - Ganaxolona NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 show 16 more results16.8%Double Blind: Cohort 2 - Ganaxolon NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 —Open Label: Ganaxolone in Double-b NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 —Open Label: Placebo in Double-blin NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 — NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3 7.8% NCT05323734 · Phase 3 · registry result, not featured evidence 10% NCT03865732 · Phase 2 · registry result, not featured evidence —High NCT03350035 · Phase 2 · registry result, not featured evidence —Low NCT03350035 · Phase 2 · registry result, not featured evidence —Medium NCT03350035 · Phase 2 · registry result, not featured evidence 0%CDKL5 NCT02358538 · Phase 2 · registry result, not featured evidence 50%CSWS NCT02358538 · Phase 2 · registry result, not featured evidence 10%Lennox-Gastaut NCT02358538 · Phase 2 · registry result, not featured evidence 18.2%PCDH19 NCT02358538 · Phase 2 · registry result, not featured evidence 10.6% NCT00512317 · Phase 2 · registry result, not featured evidence 9.1% NCT01002820 · Phase 2 · registry result, not featured evidence 7.1% NCT00465517 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%Double Blind: Cohort 1 - Ganaxolona NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 show 16 more results5%Double Blind: Cohort 2 - Ganaxolon NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 7.6%Open Label: Ganaxolone in Double-b NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 6.9%Open Label: Placebo in Double-blin NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 37.3% NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3 7.8% NCT05323734 · Phase 3 · registry result, not featured evidence 10% NCT03865732 · Phase 2 · registry result, not featured evidence 25%High NCT03350035 · Phase 2 · registry result, not featured evidence 40%Low NCT03350035 · Phase 2 · registry result, not featured evidence 50%Medium NCT03350035 · Phase 2 · registry result, not featured evidence 14.3%CDKL5 NCT02358538 · Phase 2 · registry result, not featured evidence 50%CSWS NCT02358538 · Phase 2 · registry result, not featured evidence 20%Lennox-Gastaut NCT02358538 · Phase 2 · registry result, not featured evidence 27.3%PCDH19 NCT02358538 · Phase 2 · registry result, not featured evidence 12.2% NCT00512317 · Phase 2 · registry result, not featured evidence 9.1% NCT01002820 · Phase 2 · registry result, not featured evidence 5.1% NCT00465517 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a ataxia 12.5% (placebo 0%) sedation 12.5% (placebo 0%) somnolence 12.5% (placebo 9.5%) NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 show 16 more resultssomnolence 22.3% (placebo 9.5%) dizziness 19% (placebo 0%) fatigue 11.7% (placebo 0%) NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 somnolence 7.6% (placebo 9.5%) fatigue 5.7% (placebo 0%) headache 5.7% (placebo 0%) NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 somnolence 16.8% (placebo 9.5%) dizziness 15.6% (placebo 0%) fatigue 8.7% (placebo 0%) NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 hypotension 23.5% (placebo 16.3%) urinary tract infection 19.6% (placebo 8.2%) hypothermia 9.8% (placebo 4.1%) NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3 somnolence 28.1% (placebo 16.9%) pyrexia 15.6% (placebo 16.9%) fatigue 14.1% (placebo 9.2%) NCT05323734 · Phase 3 · registry result, not featured evidence somnolence 40% (placebo 27.3%) aggression 20% (placebo 9.1%) agitation 20% (placebo 0%) NCT03865732 · Phase 2 · registry result, not featured evidence High somnolence 37.5% hypercaprnia 25% hypocalcaemia 25% NCT03350035 · Phase 2 · registry result, not featured evidence Low hypotension 40% haematuria 20% pain 20% NCT03350035 · Phase 2 · registry result, not featured evidence Medium hypokalaemia 25% pain 25% pneumonia 25% NCT03350035 · Phase 2 · registry result, not featured evidence pyrexia 71.4% upper respiratory tract infection 42.9% vomiting 42.9% NCT02358538 · Phase 2 · registry result, not featured evidence dizziness 50% sinusitis 50% somnolence 50% NCT02358538 · Phase 2 · registry result, not featured evidence fungal infection 20% hypersomnia 20% seizure 20% NCT02358538 · Phase 2 · registry result, not featured evidence pyrexia 63.6% somnolence 54.5% fatigue 36.4% NCT02358538 · Phase 2 · registry result, not featured evidence headache 21.1% convulsion 16.3% fatigue 16.3% NCT00512317 · Phase 2 · registry result, not featured evidence headache 18.2% irritability 18.2% aortic aneurysm 9.1% NCT01002820 · Phase 2 · registry result, not featured evidence dizziness 16.3% (placebo 8.2%) fatigue 16.3% (placebo 8.2%) somnolence 13.3% (placebo 2%) NCT00465517 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 12 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ganaxolone
show 1 more result
show 1 more result
+ 41 further endpoints in the CSV export.
Developmental and Epileptic Encephalopathies
Shared mechanism: GABA-A receptor · full Developmental and Epileptic Encephalopathies pipeline
Ganaxolone
Marketed by Immedica Pharma AB
NCT03572933 · Phase 3 · completed
Marigold was a randomized, double-blind, placebo-controlled Phase 3 trial in 101 patients aged 2 to 21 with CDKL5 deficiency disorder. The primary endpoint was the percentage change in 28-day major motor seizure frequency over 17 weeks: -30.7% with ganaxolone vs -6.9% with placebo (p=0.0036), so the primary was met. Source: the peer-reviewed paper (Knight et al., Lancet Neurol 2022).
Reported efficacy
Summary of 28-day Seizure Frequency for Major Motor Seizure Types (End of the double-blind 17 week treatment period): Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022). (met)
Result source: NCT03572933
Stiripentol
Marketed by Biocodex
NCT07176832 · Phase 1 · completed
This is an open-label pharmacokinetic bioequivalence study comparing two formulations of the same already-marketed drug in healthy volunteers, not a controlled trial measuring clinical efficacy against a comparator or placebo.
No aligned efficacy figure on record for this race.
Results for Developmental and Epileptic Encephalopathies
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Stiripentol: no structured comparison results are available for Developmental and Epileptic Encephalopathies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ganaxolone
Available safety results
Ganaxolone
| Dropout rate | 4% NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3 |
|---|---|
| Discontinued due to AEs | 2% NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3 |
| Serious AEs | 12% NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3 |
| Most frequent reported AEs | somnolence 36% (placebo 15.7%) pyrexia 18% (placebo 7.8%) seizure 14% (placebo 17.6%) NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3 |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ganaxolone's landscape · Stiripentol's landscape